A 42-year-old woman with a BMI of 34 kg/m² presents to the dermatology clinic with a 6-month history of progressive darkening and thickening of the skin over her neck, armpits, and groin folds. On examination, the affected areas show symmetric, hyperpigmented, velvety plaques as marked **A** in the diagram. Laboratory investigations reveal fasting glucose 118 mg/dL, fasting insulin 22 mIU/L (normal <12), and HbA1c 6.8%. Which of the following best explains the pathophysiology of the cutaneous lesion marked **A**?
A. Autoimmune destruction of melanocytes in flexural areas due to cross-reactivity with insulin receptor epitopes
B. Direct binding of elevated cortisol to glucocorticoid receptors on melanocytes, causing increased melanin synthesis
C. Hyperinsulinemia leading to spillover binding of insulin to IGF-1R on keratinocytes and fibroblasts, stimulating proliferation
D. Increased activity of tyrosinase secondary to chronic sun exposure in intertriginous areas
Explanation
Why option 1 is right
The velvety hyperpigmented flexural plaque marked A is acanthosis nigricans (AN), a cutaneous manifestation of insulin resistance. In obesity-associated AN, the pathophysiology is driven by hyperinsulinemia secondary to insulin resistance. Elevated insulin levels spill over to bind insulin-like growth factor receptor-1 (IGF-1R) on keratinocytes and fibroblasts, stimulating their proliferation and resulting in the characteristic symmetric, velvety thickening and hyperpigmentation of flexural areas (posterior neck, axillae, groin, antecubital and popliteal fossae). This mechanism is well-established in Bolognia Dermatology and Endocrine Society Guidelines and is the hallmark pathophysiology of obesity-associated AN.
Why each distractor is wrong
Option 2: While glucocorticoids can cause drug-induced AN, the primary mechanism is not direct cortisol-melanocyte interaction. Moreover, this patient has no history of glucocorticoid use, and her laboratory profile clearly indicates insulin resistance, not glucocorticoid excess.
Option 3: AN is not an autoimmune condition. There is no evidence of autoimmune destruction of melanocytes or cross-reactivity with insulin receptor epitopes in the pathophysiology of AN. The condition is driven by growth factor receptor activation, not immune-mediated melanocyte loss.
Option 4: Tyrosinase activity and sun exposure play no role in the pathophysiology of AN. AN occurs in flexural (sun-protected) areas and is driven by insulin-mediated growth factor signaling, not melanin synthesis pathways. This is a distractor based on confusion with other hyperpigmentary disorders.
